Elizabeth Reed Sells 10,000 Shares of Travere Therapeutics Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced that insider Elizabeth Reed sold 10,000 shares of the company’s stock on January 20, 2023. The shares were sold at an average price of $27.34, resulting in a total transaction value of $273,400. Following this sale, Reed now holds 90,270 shares, valued at approximately $2,467,981.80. This transaction represents a decrease of 9.97% in Reed’s holdings. The details of the sale were disclosed in a legal filing with the U.S. Securities and Exchange Commission (SEC).

Stock Performance and Financial Overview

As of last Friday, shares of Travere Therapeutics opened at $29.73. The company currently maintains a debt-to-equity ratio of 4.23, with a quick ratio of 2.71 and a current ratio of 2.75. Travere’s market capitalization stands at $2.66 billion, with a price-to-earnings (P/E) ratio of -28.05. The firm’s fifty-day moving average is $34.79, while the two-hundred-day moving average is $26.77. Over the past year, Travere has seen a 52-week low of $12.91 and a high of $42.13.

In its latest quarterly earnings report, released on October 30, 2023, Travere Therapeutics reported earnings per share (EPS) of $0.28, surpassing the consensus estimate of ($0.31) by $0.59. The company’s revenue for the quarter reached $164.86 million, significantly exceeding the expected $106.09 million. This marks a year-over-year revenue increase of 162.1%, compared to the same quarter from the previous year when the firm reported an EPS of ($0.70). Analysts project Travere Therapeutics will report an EPS of -1.4 for the current fiscal year.

Analyst Ratings and Institutional Trading

Recent updates from analysts reflect a generally optimistic outlook for Travere Therapeutics. Citigroup raised its price target on the stock from $34.00 to $48.00, assigning it a “buy” rating. Additionally, TD Cowen reaffirmed a “buy” rating on October 31, 2023. Other notable updates include an upgrade from Wall Street Zen, which shifted its rating from “buy” to “strong-buy” on December 13, 2023. Guggenheim maintained a “buy” rating with a price target of $49.00, while Zacks Research downgraded the stock from “strong-buy” to “hold” on November 12, 2023. Overall, twelve research analysts have rated Travere Therapeutics as a buy, three as hold, and one as sell, resulting in an average rating of “Moderate Buy” with a target price of $38.86.

Institutional investors have been actively trading shares of Travere Therapeutics. Notably, Capital Fund Management S.A. acquired a new stake in the company valued at $1,501,000. Emerald Advisers LLC increased its holdings by 2.6% in the third quarter, now owning 2,146,767 shares worth $51,308,000 after acquiring an additional 55,407 shares. Squarepoint Ops LLC saw a remarkable 98.7% increase in its holdings during the same period, now owning 479,394 shares valued at $7,095,000. Other notable investors include Voya Investment Management LLC and Y Intercept Hong Kong Ltd, which have also expanded their stakes in the company.

Company Overview

Travere Therapeutics, Inc., based in San Diego, California, is a biopharmaceutical company dedicated to developing and commercializing therapies for rare kidney and genetic disorders. The company focuses on addressing unmet medical needs for conditions affecting small patient populations. Its lead product, sparsentan, is a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S. Food and Drug Administration (FDA).

As Travere Therapeutics continues to navigate the complex landscape of biopharmaceutical development, its recent stock transaction and ongoing financial performance will be closely monitored by investors and analysts alike.